{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,19]],"date-time":"2026-01-19T09:43:54Z","timestamp":1768815834538,"version":"3.49.0"},"reference-count":50,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2022,11,9]],"date-time":"2022-11-09T00:00:00Z","timestamp":1667952000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,11,9]],"date-time":"2022-11-09T00:00:00Z","timestamp":1667952000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100004442","name":"Narodowym Centrum Nauki","doi-asserted-by":"publisher","award":["2019\/34\/E\/NZ7\/00454"],"award-info":[{"award-number":["2019\/34\/E\/NZ7\/00454"]}],"id":[{"id":"10.13039\/501100004442","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Neurochem Res"],"published-print":{"date-parts":[[2023,3]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Anxiety is a common mental disorder, and its prevalence has lately increased because of the COVID-19 pandemic. Unfortunately, the available anxiolytics are often ineffective, and most possess addictive potential. Thus, searching for novel compounds is essential. In our previous studies, we selected a multimodal compound, HBK-15, which showed a fast antidepressant-like effect in animal models of depression. HBK-15 demonstrated a high affinity for serotonin 5-HT<jats:sub>1A<\/jats:sub> receptors and moderate for 5-HT<jats:sub>7<\/jats:sub>, dopamine D<jats:sub>2<\/jats:sub>, and \u03b1<jats:sub>1<\/jats:sub>-adrenoceptors. Based on the receptor profile and preliminary studies, we aimed to investigate the anxiolytic potential of HBK-15 using the conditioned-response rat model of anxiety, i.e., the Vogel drinking test. We performed hot plate and free-drinking tests to exclude false positive results in the Vogel test. Using radioligand binding studies, we also investigated the affinity of the compound for the\u00a0selected biological targets, which play a role in anxiety. Our experiments revealed that HBK-15 showed an anxiolytic-like effect in rats (5\u00a0mg\/kg) without influencing the pain threshold or the\u00a0amount of water consumed in the free-drinking test. Furthermore, the tested compound did not show a significant affinity for the selected biological targets, which suggests that its anxiolytic-like mechanism of action could be connected with the interaction with other receptors. This study indicates that multimodal compounds with a receptor profile similar to HBK-15 could be an attractive therapeutic option for patients with a\u00a0generalized anxiety disorder. However, more studies are required to determine the exact mechanism of action of HBK-15 and its safety profile.<\/jats:p>","DOI":"10.1007\/s11064-022-03802-x","type":"journal-article","created":{"date-parts":[[2022,11,9]],"date-time":"2022-11-09T10:03:24Z","timestamp":1667988204000},"page":"839-845","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["HBK-15, a Multimodal Compound, Showed an Anxiolytic-Like Effect in Rats"],"prefix":"10.1007","volume":"48","author":[{"given":"Klaudia","family":"Lustyk","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kinga","family":"Sa\u0142aciak","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Magdalena","family":"Jakubczyk","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Magdalena","family":"Jastrz\u0119bska-Wi\u0119sek","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anna","family":"Partyka","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anna","family":"Weso\u0142owska","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Henryk","family":"Marona","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Karolina","family":"Pytka","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2022,11,9]]},"reference":[{"key":"3802_CR1","unstructured":"Mental health. https:\/\/www.who.int\/health-topics\/mental-health#tab=tab_2. Accessed 18 Aug 2022"},{"key":"3802_CR2","doi-asserted-by":"publisher","first-page":"370","DOI":"10.1093\/pubmed\/fdv114","volume":"37","author":"G Henderson","year":"2015","unstructured":"Henderson G (2015) Addressing the public\u2019s mental health. J Public Health (Oxf) 37:370\u2013372","journal-title":"J Public Health (Oxf)"},{"key":"3802_CR3","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1007\/978-981-32-9705-0_15","volume":"1191","author":"AE Meuret","year":"2020","unstructured":"Meuret AE, Tunnell N, Roque A (2020) Anxiety disorders and medical comorbidity: treatment implications. Adv Exp Med Biol 1191:237\u2013261. https:\/\/doi.org\/10.1007\/978-981-32-9705-0_15","journal-title":"Adv Exp Med Biol"},{"key":"3802_CR4","doi-asserted-by":"publisher","first-page":"382","DOI":"10.1016\/j.psychres.2012.07.016","volume":"200","author":"I Plaisier","year":"2012","unstructured":"Plaisier I, de Graaf R, de Bruijn J et al (2012) Depressive and anxiety disorders on-the-job: the importance of job characteristics for good work functioning in persons with depressive and anxiety disorders. Psychiatry Res 200:382\u2013388. https:\/\/doi.org\/10.1016\/j.psychres.2012.07.016","journal-title":"Psychiatry Res"},{"key":"3802_CR5","unstructured":"COVID-19 pandemic triggers 25% increase in prevalence of anxiety and depression worldwide. https:\/\/www.who.int\/news\/item\/02-03-2022-covid-19-pandemic-triggers-25-increase-in-prevalence-of-anxiety-and-depression-worldwide. Accessed 18 Aug 2022"},{"key":"3802_CR6","doi-asserted-by":"publisher","first-page":"1","DOI":"10.12688\/f1000research.24457.1","volume":"9","author":"MM Hossain","year":"2020","unstructured":"Hossain MM, Tasnim S, Sultana A et al (2020) Epidemiology of mental health problems in COVID-19: a review. F1000Research 9:1\u201316","journal-title":"F1000Research"},{"key":"3802_CR7","doi-asserted-by":"publisher","first-page":"260","DOI":"10.1016\/j.encep.2013.11.002","volume":"41","author":"G Ammar","year":"2015","unstructured":"Ammar G, Naja WJ, Pelissolo A (2015) Treatment-resistant anxiety disorders: a literature review of drug therapy strategies. Encephale 41:260\u2013265. https:\/\/doi.org\/10.1016\/j.encep.2013.11.002","journal-title":"Encephale"},{"key":"3802_CR8","doi-asserted-by":"publisher","first-page":"595584","DOI":"10.3389\/fpsyt.2020.595584","volume":"11","author":"A Garakani","year":"2020","unstructured":"Garakani A, Murrough JW, Freire RC et al (2020) Pharmacotherapy of anxiety disorders: current and emerging treatment options. Front Psychiatry 11:595584. https:\/\/doi.org\/10.3389\/fpsyt.2020.595584","journal-title":"Front Psychiatry"},{"key":"3802_CR9","doi-asserted-by":"publisher","first-page":"87","DOI":"10.31887\/DCNS.2017.19.2\/fthibaut","volume":"19","author":"F Thibaut","year":"2017","unstructured":"Thibaut F (2017) Anxiety disorders: a review of current literature. Dialogues Clin Neurosci 19:87\u201388. https:\/\/doi.org\/10.31887\/DCNS.2017.19.2\/fthibaut","journal-title":"Dialogues Clin Neurosci"},{"key":"3802_CR10","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1016\/j.jpsychires.2019.08.009","volume":"118","author":"H He","year":"2019","unstructured":"He H, Xiang Y, Gao F et al (2019) Comparative efficacy and acceptability of first-line drugs for the acute treatment of generalized anxiety disorder in adults: a network meta-analysis. J Psychiatr Res 118:21\u201330. https:\/\/doi.org\/10.1016\/j.jpsychires.2019.08.009","journal-title":"J Psychiatr Res"},{"key":"3802_CR11","doi-asserted-by":"publisher","first-page":"CD00611","DOI":"10.1002\/14651858.CD006115","volume":"2006","author":"CA Chessick","year":"2006","unstructured":"Chessick CA, Allen MH, Thase M et al (2006) Azapirones for generalized anxiety disorder. Cochrane Database Syst Rev 2006:CD00611. https:\/\/doi.org\/10.1002\/14651858.CD006115","journal-title":"Cochrane Database Syst Rev"},{"key":"3802_CR12","doi-asserted-by":"publisher","first-page":"326","DOI":"10.1111\/cbdd.12394","volume":"85","author":"AM Waszkielewicz","year":"2014","unstructured":"Waszkielewicz AM, Pytka K, Rapacz A et al (2014) Synthesis and evaluation of antidepressant-like activity of some 4-substituted 1-(2-methoxyphenyl) piperazine derivatives. Chem Biol Drug Des 85:326\u2013335. https:\/\/doi.org\/10.1111\/cbdd.12394","journal-title":"Chem Biol Drug Des"},{"key":"3802_CR13","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1016\/j.bbr.2017.06.032","volume":"333","author":"K Pytka","year":"2017","unstructured":"Pytka K, G\u0142uch-Lutwin M, Kota\u0144ska M et al (2017) HBK-15 protects mice from stress-induced behavioral disturbances and changes in corticosterone, BDNF, and NGF levels. Behav Brain Res 333:54\u201366. https:\/\/doi.org\/10.1016\/j.bbr.2017.06.032","journal-title":"Behav Brain Res"},{"key":"3802_CR14","doi-asserted-by":"publisher","first-page":"229","DOI":"10.3389\/fphar.2016.00229","volume":"7","author":"K Pytka","year":"2016","unstructured":"Pytka K, Lustyk K, \u017bmudzka E et al (2016) Chemically homogenous compounds with antagonistic properties at all \u03b11-adrenoceptor subtypes but not \u03b21-adrenoceptor attenuate adrenaline-induced arrhythmia in rats. Front Pharmacol 7:229. https:\/\/doi.org\/10.3389\/fphar.2016.00229","journal-title":"Front Pharmacol"},{"key":"3802_CR15","doi-asserted-by":"publisher","first-page":"3931","DOI":"10.1007\/s12035-017-0605-4","volume":"55","author":"K Pytka","year":"2018","unstructured":"Pytka K, G\u0142uch-Lutwin M, Kota\u0144ska M et al (2018) Single administration of HBK-15\u2014a triple 5-HT1A, 5-HT7, and 5-HT3 receptor antagonist\u2014reverses depressive-like behaviors in mouse model of depression induced by corticosterone. Mol Neurobiol 55:3931\u20133945. https:\/\/doi.org\/10.1007\/s12035-017-0605-4","journal-title":"Mol Neurobiol"},{"key":"3802_CR16","doi-asserted-by":"publisher","first-page":"e0142499","DOI":"10.1371\/journal.pone.0142499","volume":"10","author":"K Pytka","year":"2015","unstructured":"Pytka K, Partyka A, Jastrz\u0119bska-Wi\u0119sek M et al (2015) Antidepressant- and anxiolytic-like effects of new dual 5-HT1A and 5-HT7 antagonists in animal models. PLoS ONE 10:e0142499. https:\/\/doi.org\/10.1371\/journal.pone.0142499","journal-title":"PLoS ONE"},{"issue":"1","key":"3802_CR17","first-page":"166","volume":"50","author":"PA Witt-Enderby","year":"1996","unstructured":"Witt-Enderby PA, Dubocovich ML (1996) Characterization and regulation of the human ML1A melatonin receptor stably expressed in Chinese hamster ovary cells. Mol Pharmacol 50(1):166\u2013174","journal-title":"Mol Pharmacol"},{"key":"3802_CR18","first-page":"1239","volume":"285","author":"IJM Beresford","year":"1998","unstructured":"Beresford IJM, Browning C, Starkey SJ et al (1998) GR196429: a nonindolic agonist at high-affinity melatonin receptors. J Pharmacol Exp Ther 285:1239\u20131245","journal-title":"J Pharmacol Exp Ther"},{"key":"3802_CR19","doi-asserted-by":"publisher","first-page":"2373","DOI":"10.1016\/S0021-9258(17)41954-5","volume":"269","author":"A Townsend-Nicholson","year":"1994","unstructured":"Townsend-Nicholson A, Schofield PR (1994) A threonine residue in the seventh transmembrane domain of the human A1 adenosine receptor mediates specific agonist binding. J Biol Chem 269:2373\u20132376","journal-title":"J Biol Chem"},{"key":"3802_CR20","first-page":"307","volume":"47","author":"DR Luthin","year":"1995","unstructured":"Luthin DR, Olsson RA, Thompson RD et al (1995) Characterization of two affinity states of adenosine A2a receptors with a new radioligand, 2-[2-(4-amino-3-[125I]iodophenyl)ethylamino]adenosine. Mol Pharmacol 47:307\u2013313","journal-title":"Mol Pharmacol"},{"key":"3802_CR21","doi-asserted-by":"publisher","first-page":"384","DOI":"10.1210\/mend.6.3.1584214","volume":"6","author":"JH Stehle","year":"1992","unstructured":"Stehle JH, Rivkees SA, Lee JJ et al (1992) Molecular cloning and expression of the cDNA for a novel A2-adenosine receptor subtype. Mol Endocrinol 6:384\u2013393. https:\/\/doi.org\/10.1210\/mend.6.3.1584214","journal-title":"Mol Endocrinol"},{"key":"3802_CR22","doi-asserted-by":"publisher","first-page":"10365","DOI":"10.1073\/pnas.90.21.10365","volume":"90","author":"CA Salvatore","year":"1993","unstructured":"Salvatore CA, Jacobson MA, Taylort HE et al (1993) Molecular cloning and characterization of the human A3 adenosine receptor. Proc Natl Acad Sci USA 90:10365\u201310369","journal-title":"Proc Natl Acad Sci USA"},{"key":"3802_CR23","first-page":"143","volume":"275","author":"HA Wieland","year":"1995","unstructured":"Wieland HA, Willim KD, Entzeroth M et al (1995) Subtype selectivity and antagonistic profile of the nonpeptide Y1 receptor antagonist BIBP 3226. J Pharmacol Exp Ther 275:143\u2013149","journal-title":"J Pharmacol Exp Ther"},{"key":"3802_CR24","doi-asserted-by":"publisher","first-page":"182","DOI":"10.1073\/pnas.87.1.182","volume":"87","author":"J Fuhlendorff","year":"1990","unstructured":"Fuhlendorff J, Gether U, Aakerlund L et al (1990) [Leu31, Pro34]neuropeptide Y: a specific Y1 receptor agonist. Proc Natl Acad Sci USA 87:182\u2013186. https:\/\/doi.org\/10.1073\/pnas.87.1.182","journal-title":"Proc Natl Acad Sci USA"},{"key":"3802_CR25","first-page":"289","volume":"276","author":"M Gopalakrishnan","year":"1996","unstructured":"Gopalakrishnan M, Monteggia LM, Anderson DJ et al (1996) Stable expression, pharmacologic properties and regulation of the human neuronal nicotinic acetylcholine alpha 4 beta 2 receptor. J Pharmacol Exp Ther 276:289\u2013297","journal-title":"J Pharmacol Exp Ther"},{"key":"3802_CR26","doi-asserted-by":"publisher","first-page":"2783","DOI":"10.1523\/JNEUROSCI.20-08-02783.2000","volume":"20","author":"CGV Sharples","year":"2000","unstructured":"Sharples CGV, Kaiser S, Soliakov L et al (2000) UB-165: a novel nicotinic agonist with subtype selectivity implicates the \u03b14\u03b22* subtype in the modulation of dopamine release from rat striatal synaptosomes. J Neurosci 20:2783\u20132791. https:\/\/doi.org\/10.1523\/JNEUROSCI.20-08-02783.2000","journal-title":"J Neurosci"},{"key":"3802_CR27","doi-asserted-by":"publisher","first-page":"340","DOI":"10.1038\/sj.bjp.0705610","volume":"141","author":"CJ Langmead","year":"2004","unstructured":"Langmead CJ, Jerman JC, Brough SJ et al (2004) Characterisation of the binding of [3H]-SB-674042, a novel nonpeptide antagonist, to the human orexin-1 receptor. Br J Pharmacol 141:340\u2013346. https:\/\/doi.org\/10.1038\/sj.bjp.0705610","journal-title":"Br J Pharmacol"},{"key":"3802_CR28","doi-asserted-by":"publisher","first-page":"1128","DOI":"10.1046\/J.0014-2956.2001.02739.X","volume":"269","author":"HA Wieland","year":"2002","unstructured":"Wieland HA, S\u00f6ll RM, Doods HN et al (2002) The SK-N-MC cell line expresses an orexin binding site different from recombinant orexin\u20031-type receptor. Eur J Biochem 269:1128\u20131135. https:\/\/doi.org\/10.1046\/J.0014-2956.2001.02739.X","journal-title":"Eur J Biochem"},{"key":"3802_CR29","doi-asserted-by":"publisher","first-page":"1071","DOI":"10.1111\/j.1476-5381.1996.tb16699.x","volume":"117","author":"MJ Smit","year":"1996","unstructured":"Smit MJ, Timmerman H, Hijzelendoorn JC et al (1996) Regulation of the human histamine H1 receptor stably expressed in Chinese hamster ovary cells. Br J Pharmacol 117:1071\u20131080. https:\/\/doi.org\/10.1111\/j.1476-5381.1996.tb16699.x","journal-title":"Br J Pharmacol"},{"key":"3802_CR30","doi-asserted-by":"publisher","first-page":"847","DOI":"10.1111\/j.1476-5381.1994.tb13157.x","volume":"112","author":"R Leurs","year":"1994","unstructured":"Leurs R, Smit MJ, Menge WM, Timmerman H (1994) Pharmacological characterization of the human histamine H2 receptor stably expressed in Chinese hamster ovary cells. Br J Pharmacol 112:847\u2013854. https:\/\/doi.org\/10.1111\/j.1476-5381.1994.tb13157.x","journal-title":"Br J Pharmacol"},{"key":"3802_CR31","doi-asserted-by":"publisher","first-page":"1101","DOI":"10.1124\/mol.55.6.1101","volume":"55","author":"TW Lovenberg","year":"1999","unstructured":"Lovenberg TW, Roland BL, Wilson SJ et al (1999) Cloning and functional expression of the human histamine H3 receptor. Mol Pharmacol 55:1101\u20131107","journal-title":"Mol Pharmacol"},{"key":"3802_CR32","first-page":"727","volume":"256","author":"F D\u00f6rje","year":"1991","unstructured":"D\u00f6rje F, Wess J, Lambrecht G et al (1991) Antagonist binding profiles of five cloned human muscarinic receptor subtypes. J Pharmacol Exp Ther 256:727\u2013733","journal-title":"J Pharmacol Exp Ther"},{"key":"3802_CR33","doi-asserted-by":"publisher","first-page":"3923","DOI":"10.1002\/j.1460-2075.1987.tb02733.x","volume":"6","author":"EG Peralta","year":"1987","unstructured":"Peralta EG, Ashkenazi A, Winslow JW et al (1987) Distinct primary structures, ligand-binding properties and tissue-specific expression of four human muscarinic acetylcholine receptors. EMBO J 6:3923\u20133929","journal-title":"EMBO J"},{"key":"3802_CR34","doi-asserted-by":"publisher","first-page":"2007","DOI":"10.1111\/j.1471-4159.1990.tb04905.x","volume":"54","author":"RP Shank","year":"1990","unstructured":"Shank RP, Baldy WJ, Mattucci LC, Villani FJJ (1990) Ion and temperature effects on the binding of gamma-aminobutyrate to its receptors and the high-affinity transport system. J Neurochem 54:2007\u20132015. https:\/\/doi.org\/10.1111\/j.1471-4159.1990.tb04905.x","journal-title":"J Neurochem"},{"key":"3802_CR35","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/BF00403989","volume":"21","author":"JR Vogel","year":"1971","unstructured":"Vogel JR, Beer B, Clody DE (1971) A simple and reliable conflict procedure for testing anti-anxiety agents. Psychopharmacologia 21:1\u20137. https:\/\/doi.org\/10.1007\/BF00403989","journal-title":"Psychopharmacologia"},{"key":"3802_CR36","first-page":"591","volume":"18","author":"M-R Zarrindast","year":"2015","unstructured":"Zarrindast M-R, Khakpai F (2015) The modulatory role of dopamine in anxiety-like behavior. Arch Iran Med 18:591\u2013603","journal-title":"Arch Iran Med"},{"key":"3802_CR37","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1016\/j.neuropharm.2014.12.028","volume":"96","author":"MR Picciotto","year":"2015","unstructured":"Picciotto MR, Lewis AS, van Schalkwyk GI, Mineur YS (2015) Mood and anxiety regulation by nicotinic acetylcholine receptors: a potential pathway to modulate aggression and related behavioral states. Neuropharmacology 96:235\u2013243. https:\/\/doi.org\/10.1016\/j.neuropharm.2014.12.028","journal-title":"Neuropharmacology"},{"key":"3802_CR38","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1111\/jnc.14841","volume":"151","author":"D van Calker","year":"2019","unstructured":"van Calker D, Biber K, Domschke K, Serchov T (2019) The role of adenosine receptors in mood and anxiety disorders. J Neurochem 151:11\u201327. https:\/\/doi.org\/10.1111\/jnc.14841","journal-title":"J Neurochem"},{"key":"3802_CR39","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1016\/j.lfs.2018.08.050","volume":"210","author":"E \u017bmudzka","year":"2018","unstructured":"\u017bmudzka E, Sa\u0142aciak K, Sapa J, Pytka K (2018) Serotonin receptors in depression and anxiety: insights from animal studies. Life Sci 210:106\u2013124. https:\/\/doi.org\/10.1016\/j.lfs.2018.08.050","journal-title":"Life Sci"},{"key":"3802_CR40","doi-asserted-by":"publisher","first-page":"378","DOI":"10.1016\/j.pnpbp.2017.07.013","volume":"79","author":"K Pytka","year":"2017","unstructured":"Pytka K, Soca\u0142a K, Rapacz A et al (2017) HBK-14 and HBK-15, triple 5-HT1A, 5-HT7 and 5-HT3 antagonists with potent antidepressant- and anxiolytic-like properties, increase seizure threshold in various seizure tests in mice. Prog Neuro-Psychopharmaco Biol Psychiatry 79:378\u2013385. https:\/\/doi.org\/10.1016\/j.pnpbp.2017.07.013","journal-title":"Prog Neuro-Psychopharmaco Biol Psychiatry"},{"key":"3802_CR41","doi-asserted-by":"publisher","first-page":"e0165495","DOI":"10.1371\/journal.pone.0165495","volume":"11","author":"K Pytka","year":"2016","unstructured":"Pytka K, G\u0142uch-Lutwin M, Knutelska J et al (2016) HBK-14 and HBK-15 do not influence blood pressure, lipid profile, glucose level, or liver enzymes activity after chronic treatment in rats. PLoS ONE 11:e0165495. https:\/\/doi.org\/10.1371\/journal.pone.0165495","journal-title":"PLoS ONE"},{"key":"3802_CR42","doi-asserted-by":"publisher","first-page":"547","DOI":"10.1007\/s11011-016-9932-9","volume":"32","author":"K Pytka","year":"2017","unstructured":"Pytka K, Gawlik K, Pawlica-Gosiewska D et al (2017) HBK-14 and HBK-15 with antidepressant-like and\/or memory-enhancing properties increase serotonin levels in the hippocampus after chronic treatment in mice. Metab Brain Dis 32:547\u2013556. https:\/\/doi.org\/10.1007\/s11011-016-9932-9","journal-title":"Metab Brain Dis"},{"key":"3802_CR43","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1590\/S0365-05962010000200010","volume":"85","author":"PR Criado","year":"2010","unstructured":"Criado PR, Fachini R, Criado J et al (2010) Histamine, histamine receptors and antihistamines: new concepts. An Bras Dermatol 85:195\u2013210","journal-title":"An Bras Dermatol"},{"key":"3802_CR44","unstructured":"Naji A, Gatling J (2021) Muscarinic antagonists\u2014StatPearls\u2014NCBI Bookshelf. In: StatPearls. https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK557541\/. Accessed 18 Aug 2022"},{"key":"3802_CR45","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1007\/978-1-61779-313-4_10","volume":"63","author":"JM Witkin","year":"2011","unstructured":"Witkin JM (2011) A vogel conflict test using food reinforcement in mice. Neuromethods 63:159\u2013169. https:\/\/doi.org\/10.1007\/978-1-61779-313-4_10","journal-title":"Neuromethods"},{"key":"3802_CR46","doi-asserted-by":"publisher","first-page":"1492","DOI":"10.3389\/FPSYT.2021.711065\/BIBTEX","volume":"12","author":"TA Lovick","year":"2021","unstructured":"Lovick TA, Zangrossi H (2021) Effect of estrous cycle on behavior of females in rodent tests of anxiety. Front Psychiatry 12:1492. https:\/\/doi.org\/10.3389\/FPSYT.2021.711065\/BIBTEX","journal-title":"Front Psychiatry"},{"key":"3802_CR47","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1590\/1516-4446-2017-0015","volume":"41","author":"IM Linares","year":"2019","unstructured":"Linares IM, Zuardi AW, Pereira LC et al (2019) Cannabidiol presents an inverted U-shaped dose-response curve in a simulated public speaking test. Rev Bras Psiquiatr 41:9\u201314. https:\/\/doi.org\/10.1590\/1516-4446-2017-0015","journal-title":"Rev Bras Psiquiatr"},{"key":"3802_CR48","doi-asserted-by":"publisher","first-page":"259","DOI":"10.3389\/FPHAR.2017.00259\/BIBTEX","volume":"8","author":"AW Zuardi","year":"2017","unstructured":"Zuardi AW, Rodrigues NP, Silva AL et al (2017) Inverted U-shaped dose-response curve of the anxiolytic effect of cannabidiol during public speaking in real life. Front Pharmacol 8:259. https:\/\/doi.org\/10.3389\/FPHAR.2017.00259\/BIBTEX","journal-title":"Front Pharmacol"},{"key":"3802_CR49","doi-asserted-by":"publisher","first-page":"522","DOI":"10.1101\/LM.1914110","volume":"17","author":"B Salehi","year":"2010","unstructured":"Salehi B, Cordero MI, Sandi C (2010) Learning under stress: the inverted-U-shape function revisited. Learn Mem 17:522\u2013530. https:\/\/doi.org\/10.1101\/LM.1914110","journal-title":"Learn Mem"},{"key":"3802_CR50","doi-asserted-by":"publisher","DOI":"10.2201\/nonlin.003.01.002","author":"E Baldi","year":"2005","unstructured":"Baldi E, Bucherelli C (2005) The inverted \u201cU-Shaped\u201d dose-effect relationships in learning and memory: modulation of arousal and consolidation. Nonlinearity Biol Toxicol Med. https:\/\/doi.org\/10.2201\/nonlin.003.01.002","journal-title":"Nonlinearity Biol Toxicol Med"}],"container-title":["Neurochemical Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11064-022-03802-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11064-022-03802-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11064-022-03802-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,2,13]],"date-time":"2023-02-13T12:48:47Z","timestamp":1676292527000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11064-022-03802-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,11,9]]},"references-count":50,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2023,3]]}},"alternative-id":["3802"],"URL":"https:\/\/doi.org\/10.1007\/s11064-022-03802-x","relation":{},"ISSN":["0364-3190","1573-6903"],"issn-type":[{"value":"0364-3190","type":"print"},{"value":"1573-6903","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,11,9]]},"assertion":[{"value":"17 September 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 October 2022","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 October 2022","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 November 2022","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors have no relevant financial or non-financial interests to disclose.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing Interests"}}]}}